Shanghai RAAS Blood Products 上海莱士
7 significant filings since 29 May 2026: 6 on buyback and 1 on dividend. The latest, on 10 Sep 2026: 回购报告书. 1 unverified report logged, the latest on 17 Sep 2026.
自 29 May 2026 起有 7 份重大公告：buyback 6 份、dividend 1 份。最新一份（10 Sep 2026）：回购报告书。记录了 1 条未经核实的报道，最新一条见于 17 Sep 2026。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 31 Mar 2025 | 华安证券 | 谭国超,陈珈蔚 | Outperform 增持 | ▲ | Buy 买入 |
| 30 Oct 2024 | 华安证券 | 谭国超,陈珈蔚 | Buy 买入 | ▼ | Outperform 增持 |
| 29 Aug 2024 | 华安证券 | 谭国超,陈珈蔚 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Buy 买入 | 30 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。